Advertisement
Correspondence| Volume 43, ISSUE 4, P851-852, April 2017

Download started.

Ok

Complication-related removal of totally implantable venous access port systems: Do not forget the skin scar in survivors!

Published:January 24, 2017DOI:https://doi.org/10.1016/j.ejso.2016.12.017
      We greatly appreciated the recently published single-center study by Kakkos et al.
      • Kakkos A.
      • Bresson L.
      • Hudry D.
      • et al.
      Complication-related removal of totally implantable venous access port systems: does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year retrospective study of 4045 patients.
      in which they aimed “to evaluate the impact of the interval between the insertion of totally implantable venous access port system (TIVAPS) and its first use, as well as to examine the possible implication of the neutropenia-inducing potential of the chemotherapy regimens used on documented infections and consequent removal rates”. Thus, between January 2010 and December 2013, the authors prospectively included 4045 consecutive patients (median age 57 years; range: 1–89) all treated for solid tumors and requiring TIVAPS to facilitate chemotherapy administration.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kakkos A.
        • Bresson L.
        • Hudry D.
        • et al.
        Complication-related removal of totally implantable venous access port systems: does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year retrospective study of 4045 patients.
        Eur J Surg Oncol. 2016; 43: 689-695
        • Braam K.I.
        • Veening M.A.
        • Schouten-van Meeteren A.Y.
        • et al.
        Totally implantable venous access device in children with cancer lead to disfiguring scar.
        Pediatr Hematol Oncol. 2013; 30: 154-164